Please ensure Javascript is enabled for purposes of website accessibility
WHO Study Finds Remdesivir Didn't Help COVID-19 Patients
gvw_ap_news
By Associated Press
Published 4 years ago on
October 16, 2020

Share

GENEVA — A large study led by the World Health Organization suggests that the antiviral drug remdesivir did not help hospitalized COVID-19 patients, in contrast to an earlier study that made the medicine a standard of care in the United States and many other countries.

The results announced Friday do not negate the previous ones, and the WHO study was not as rigorous as the earlier one led by the U.S. National Institutes of Health. But they add to concerns about how much value the pricey drug gives because none of the studies have found it can improve survival.

The drug has not been approved for COVID-19 in the U.S., but it was authorized for emergency use after the previous study found it shortened recovery time by five days on average. It’s approved for use against COVID-19 in the United Kingdom and Europe, and is among the treatments U.S. President Donald Trump received when he was infected earlier this month.

The WHO study involved more than 11,000 patients in 30 countries. About 2,750 were randomly assigned to get remdesivir. The rest got either the malaria drug hydroxychloroquine, the immune-system booster interferon, the antiviral combo lopinavir-ritonavir, or just usual care. The other drugs have largely been ruled out for COVID-19 by previous studies, but not remdesivir.

“In this March 2020 photo provided by Gilead Sciences, a vial of the investigational drug remdesivir is visually inspected at a Gilead manufacturing site in the United States. Given through an IV, the medication is designed to interfere with an enzyme that reproduces viral genetic material. (Gilead Sciences via AP)”

The Results Have Not Been Published in a Journal or Reviewed by Independent Scientists

Death rates after 28 days, the need for breathing machines and time in the hospital were relatively similar for those given remdesivir versus usual care.

The results have not been published in a journal or reviewed by independent scientists, but were posted on a site researchers use to share results quickly.

“The big story is the finding that remdesivir produces no meaningful impact on survival,” Martin Landray, an Oxford University professor who led other coronavirus treatment research, said in a statement.

“This is a drug that has to be given by intravenous infusion for five to 10 days,” and costs about $2,550 per treatment course, he said. “COVID affects millions of people and their families around the world. We need scalable, affordable and equitable treatments.”

Dr. Margaret Harris, a WHO spokeswoman, attributed the difference in the conclusions of the two studies to the fact WHO’s was larger.

“It’s just a much higher-powered study,” she said. “It’s quadruple the number of people in all the other studies.”

Results Are Inconsistent With More Rigorous Studies and Have Not Been Fully Reviewed or Published

However, Dr. Andre Kalil, a University of Nebraska infectious disease specialist who helped lead the U.S. remdesivir study, said the WHO one was poorly designed, which makes its conclusions less reliable. Patients and doctors knew what treatment they were using, there was no placebo infusion to help avoid biased reporting of risks or benefits, there was little information about the severity of patients’ symptoms when treatments began and a lot of missing data, he said.

“Poor quality study design cannot be fixed by a large sample size, no matter how large it is,” Kalil wrote in an email.

Furthermore, the WHO study tested 10 days of remdesivir, so some patients may have been hospitalized longer than they needed to be just to finish treatment, making their length of stay look bad in comparison to others getting usual care.

Remdesivir’s maker, Gilead Sciences, said in a statement that the results are inconsistent with more rigorous studies and have not been fully reviewed or published.

DON'T MISS

Trump Says Musk, Vivek Will Form Outside Group to Advise White House on Government Efficiency

DON'T MISS

Fate of Clovis Trustee Race Still Up in the Air. So Are Clovis, Sanger School Bond Measures.

DON'T MISS

Richardson Widens Lead Over Bonakdar in Nail-Biting Race for Fresno City Council

DON'T MISS

What to Know About John Ratcliffe, Trump’s Pick for CIA Director

DON'T MISS

Here Are the People Trump Has Picked for Key Positions So Far

DON'T MISS

Waymo’s Robotaxis Now Open to Anyone Who Wants a Driverless Ride in Los Angeles

DON'T MISS

Fresno County Man Accused of Filing Fake Disability Claims in $300K Fraud Scheme

DON'T MISS

Trump Nominates Fox News Host Pete Hegseth for Defense Secretary

DON'T MISS

Economists Warn of Inflation and Debt Risks in Trump’s Second Term Plans

DON'T MISS

How Many Smoke Shops Is Too Many? Fresno Plan Would Allow Only 49

UP NEXT

Chris Wallace Is Leaving CNN, Eager to Explore New Media Landscape

UP NEXT

US Regulators Investigating Whether Engines on 1.4 Million Hondas Might Fail

UP NEXT

When to Catch the Last Supermoon of the Year

UP NEXT

Mattel Says It ‘Deeply’ Regrets Misprint on ‘Wicked’ Dolls Packaging That Links to Porn Site

UP NEXT

Trump to Target Iran’s Oil Trade in Renewed ‘Maximum Pressure’ Campaign

UP NEXT

4B Movement: After the Election, a Call for Women to Swear Off Men

UP NEXT

FBI Thwarts Iranian Murder-for-Hire Plan Targeting Donald Trump

UP NEXT

Wave of Racist Texts After Election Prompts FBI Scrutiny

UP NEXT

Americans Seek Fresh Start Abroad as Election Sparks Expat Interest

UP NEXT

Trump Promises to Bring Lasting Peace to a Tumultuous Middle East. But Fixing It Won’t Be Easy

What to Know About John Ratcliffe, Trump’s Pick for CIA Director

6 hours ago

Here Are the People Trump Has Picked for Key Positions So Far

6 hours ago

Waymo’s Robotaxis Now Open to Anyone Who Wants a Driverless Ride in Los Angeles

6 hours ago

Fresno County Man Accused of Filing Fake Disability Claims in $300K Fraud Scheme

6 hours ago

Trump Nominates Fox News Host Pete Hegseth for Defense Secretary

6 hours ago

Economists Warn of Inflation and Debt Risks in Trump’s Second Term Plans

6 hours ago

How Many Smoke Shops Is Too Many? Fresno Plan Would Allow Only 49

7 hours ago

US Says It Will Not Limit Israel Arms Transfers After Some Improvements in Flow of Aid to Gaza

7 hours ago

Who With Valley Ties Could Land Spots in the Trump Administration?

8 hours ago

Tulare Gang Member Gets Life Without Parole for 2022 Murders

9 hours ago

Trump Says Musk, Vivek Will Form Outside Group to Advise White House on Government Efficiency

WASHINGTON — President-elect Donald Trump on Tuesday said Elon Musk and former GOP presidential candidate Vivek Ramaswamy will lead a new “D...

5 hours ago

5 hours ago

Trump Says Musk, Vivek Will Form Outside Group to Advise White House on Government Efficiency

5 hours ago

Fate of Clovis Trustee Race Still Up in the Air. So Are Clovis, Sanger School Bond Measures.

5 hours ago

Richardson Widens Lead Over Bonakdar in Nail-Biting Race for Fresno City Council

6 hours ago

What to Know About John Ratcliffe, Trump’s Pick for CIA Director

6 hours ago

Here Are the People Trump Has Picked for Key Positions So Far

6 hours ago

Waymo’s Robotaxis Now Open to Anyone Who Wants a Driverless Ride in Los Angeles

A Fresno County man has been indicted on mail fraud charges for allegedly submitting over $300,000 in falsified disability claims using stolen identities. (GV Wire File)
6 hours ago

Fresno County Man Accused of Filing Fake Disability Claims in $300K Fraud Scheme

Pete Hegseth walks to an elevator for a meeting with President-elect Donald Trump at Trump Tower in New York, Dec. 15, 2016. (AP File)
6 hours ago

Trump Nominates Fox News Host Pete Hegseth for Defense Secretary

Search

Send this to a friend